Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from GILD

Why These Analysts Are Bullish On Gilead's Q1 Earnings

RBC Capital Market views Gilead Sciences Inc's (NASDAQ:GILD) Q1 as a solid quarter, with a bottom-line beat reflecting Veklury cash flow boost, solid core business performance despite seasonal headwinds, and in-line operating expenses. The analyst notes that the story remains somewhat catalyst light, especially with transformative M&A likely off the table. HIV sales,…

Benzinga

$1000 Invested In Gilead Sciences 20 Years Ago Would Be Worth This Much

Gilead Sciences (NASDAQ:GILD) has outperformed the market over the past 20 years by 7.56% on an annualized basis producing an average annual return of 14.71%. Currently, Gilead Sciences has a market capitalization of $75.20 billion.

Benzinga

Where Gilead Sciences Stands With Analysts

Over the past 3 months, 11 analysts have published their opinion on Gilead Sciences (NASDAQ:GILD) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

Gilead Sciences Q1 Results Surpass Street Expectation, FY22 Outlook Midpoint Trails Consensus

Gilead Sciences, Inc. (NASDAQ: GILD) reported firs

Benzinga

Recap: Gilead Sciences Q1 Earnings

Gilead Sciences (NASDAQ:GILD) reported its Q1 earnings results on Thursday, April 28, 2022 at 04:01 PM. Here's what investors need to know about the announcement.

Benzinga

Gilead Sciences's Earnings Outlook

Gilead Sciences (NASDAQ:GILD) is set to give its latest quarterly earnings report on Thursday, 2022-04-28. Here's what investors need to know before the announcement. Analysts estimate that Gilead Sciences will report an earnings per share (EPS) of $1.80.

Benzinga

Gilead's Remdesivir Becomes First Approved Treatment For Pediatric COVID-19 Patients

The FDA has approved Gilead Sciences Inc's (NASDAQ:GILD) supplemental marketing application for Veklury (remdesivir) for pediatric COVID-19 patients older than 28 days. The approval covers patients weighing at least 3 kg and are either hospitalized with COVID-19 or have mild-to-moderate COVID-19 and are considered high risk for progression to severe infection. This approval…

Benzinga

Read news from The Economist, FT, and more,
with one subscription

Looking for Value Stocks to Add to Your Portfolio? Here are 5 For Your List

Heightened inflationary pressure, deepening supply chain disruptions, and the possibility of aggressive interest rate hikes later this year have fostered a volatile stock market. Because these factors are not expected to abate anytime soon, we think investors looking to generate solid long-term returns could consider betting on the stocks of…

StockNews.com

If You Invested $1000 In Gilead Sciences 20 Years Ago, Here's How Much You Would Have Today

Gilead Sciences (NASDAQ:GILD) has outperformed the market over the past 20 years by 7.99% on an annualized basis producing an average annual return of 15.38%. Currently, Gilead Sciences has a market capitalization of $79.98 billion.

Benzinga

Where Gilead Sciences Stands With Analysts

Within the last quarter, Gilead Sciences (NASDAQ:GILD) has observed the following analyst ratings:

Benzinga

Here's How Much You Would Have Made Owning Gilead Sciences Stock In The Last 20 Years

Gilead Sciences (NASDAQ:GILD) has outperformed the market over the past 20 years by 6.62% on an annualized basis producing an average annual return of 13.94%. Currently, Gilead Sciences has a market capitalization of $75.77 billion.

Benzinga

10 Biggest Price Target Changes For Monday

Wells Fargo cut the price target on Gilead Sciences, Inc. (NASDAQ: GILD) from $70 to $63. Gilead Sciences shares rose 0.4% to $59.91 in pre-market trading.

Benzinga

4 Best High-Yield Stocks on the S&P 500: Phillips 66, Gilead, Valero, and Walgreen Boots

The stock market has been experiencing high volatility due to surging inflation, the Ukraine-Russia war, and multiple interest rate increases planned by the Fed this year. So, investors looking to side-step the market’s volatility could be well served by betting on high dividend-yielding stocks. Gilead Sciences (GILD), Walgreens Boots Alliance…

StockNews.com

Here's How Much You Would Have Made Owning Gilead Sciences Stock In The Last 20 Years

Gilead Sciences (NASDAQ:GILD) has outperformed the market over the past 20 years by 6.58% on an annualized basis.

Benzinga

Get all your
news in one place.

100’s of premium titles.
One news app.

StockNews.com

Trading Near 52-Week Lows: Grab These 5 Undervalued Healthcare Stocks Now

Despite possessing solid long-term growth prospects on the back of rising demand from an aging population, many healthcare stocks have been hard hit by the broader market sell-offs over the past couple of months. But given the near-inelastic demand for healthcare solutions and the industry’s long-term growth prospects, we think…

Benzinga

Gilead Sciences' Trodelvy Study In Breast Cancer Meets Primary Endpoint

Gilead Sciences Inc (NASDAQ: GILD) announced results from the Phase 3 TROPiCS-02 study evaluating Trodelvy (sacituzumab govitecan-hziy) in patients with HR+/HER2- metastatic breast cancer.

Benzinga

Gilead Hit By FDA Complete Response Letter For Lenacapavir In HIV Infection

The FDA has issued a complete response letter (CRL) for Gilead Sciences Inc's (NASDAQ:GILD) application for lenacapavir for heavily treated multi-drug resistant (MDR) HIV-1 infection. Lenacapavir is an investigational, long-acting HIV-1 capsid inhibitor. In the CRL, the FDA has cited Chemistry Manufacturing and Controls (CMC) issues relating to the compatibility of lenacapavir with the…

Benzinga

Where Gilead Sciences Stands With Analysts

Within the last quarter, Gilead Sciences (NASDAQ:GILD) has observed the following analyst ratings:

Get all your
news in one place.

100’s of premium titles.
One news app.

StockNews.com

2 Undervalued Biopharmaceutical Stocks to Scoop Up in February

Biopharma stocks have been trading at lower valuations because of uncertainties surrounding drug-pricing reform, regulatory surprises, and COVID-19. However, the biopharma industry is expected to grow in the coming years. Given the bullish analysts’ sentiment around the sector, biopharma stocks Gilead (GILD) and Exelixis (EXEL), which look undervalued at their…

Benzinga

Gilead's Lenacapavir Shows Sustained Efficacy In Pretreated HIV Patients

Gilead Sciences Inc (NASDAQ: GILD)

Benzinga

Gilead Shares Updated Data From Remdesivir Study In Pediatric COVID-19 Patients

Gilead Sciences Inc (NASDAQ: GILD)

Benzinga

If You Invested $100 In This Stock 20 Years Ago, Here's How Much You Would Have Today

Gilead Sciences (NASDAQ:GILD) has outperformed the market over the past 20 years by 7.4% on an annualized basis.

Benzinga

Gilead's Remdesivir Retains Antiviral Activity Against Several COVID-19 Variants, Including Omicron

Gilead Sciences Inc's (NASDAQ: GILD) Veklury (remdesivir) has

Benzinga

Why Jim Cramer Loves Berkshire Hathaway, Skeptical On Rivian

On CNBC’s "Mad Money Lightning Round," Jim Cramer said he is not a fan of Gilead Sciences, Inc. (NASDAQ: GILD). "They have what I call big hat, no cattle, and I like ones that have cattle," he added.

Benzinga

GSK To Get $1.25B As Settlement For HIV Treatment Drug Patent Row With Gilead

GlaxoSmithKline plc (NYSE: GSK) has settled a patent dispute between ViiV Healthcare and Gilead Sciences Inc (NASDAQ: GILD).

1 … 6 7 8 9

People

Jim Cramer

503 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.